Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF 50 Shiller PE Ratio is 154.58 as of Sep. 09, 2026, which is 1% above its 10-year median of 153.54. GuruFocus rates ZLDPF with a GF Score™ of 50/100. The stock has 5 warning signs investors should review. Among 170 Biotechnology companies, Zealand Pharma AS ranks worse than 92.35% on this metric.
The historical rank and industry rank for Zealand Pharma AS's Shiller PE Ratio or its related term are showing as below:
ZLDPF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 142.42 Med: 153.54 Max: 167.17
Current: 149.6
During the past years, Zealand Pharma AS's highest Shiller PE Ratio was 167.17. The lowest was 142.42. And the median was 153.54.
ZLDPF's Shiller PE Ratio is ranked worse than 92.35% of 170
companies
in the Biotechnology industry
Industry Median: 33.39
vs ZLDPF: 149.60
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was $8.527. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.30 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Zealand Pharma AS (OTCPK:ZLDPF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Zealand Pharma AS Shiller PE Ratio Related Terms
Zealand Pharma AS Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Zealand Pharma AS (ZLDPF) has a Shiller PE Ratio of 154.58 as of Sep. 09, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Zealand Pharma AS and its competitors. This is near median its historical median of 153.54. Over the past decade, Zealand Pharma AS's Shiller PE Ratio has ranged from 142.42 to 167.17. According to the industry distribution chart, Zealand Pharma AS ranks #157 out of 170 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Zealand Pharma AS's Shiller PE Ratio too high?
Zealand Pharma AS's current Shiller PE Ratio of 154.58 is near median its 10-year median of 153.54. Over the past 10 years, this metric has ranged from a low of 142.42 to a high of 167.17. The Biotechnology industry median Shiller PE Ratio is 33.39. Zealand Pharma AS's value of 154.58 is 363% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #157 out of 170 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Shiller PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #157 out of 170 companies for Shiller PE Ratio. This places Zealand Pharma AS in the lower half of its industry. The industry median Shiller PE Ratio is 33.39. Zealand Pharma AS's value of 154.58 is 363% above this benchmark. Historically, Zealand Pharma AS's own Shiller PE Ratio has ranged from 142.42 to 167.17 over the past decade. While the company's 10-year median is 153.54 vs. the industry median of 33.39, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 33.39, based on 170 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Shiller PE Ratio of 154.58 is 363% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 33.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Shiller PE Ratio is 154.58, which is near median its own 10-year median of 153.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPF) has a current Shiller PE Ratio of 154.58. The current Shiller PE Ratio is 154.58, which is near median its 10-year median of 153.54 and 363% above the Biotechnology industry median of 33.39. Zealand Pharma AS's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Shiller PE Ratio is 154.58 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
50GF Score
Get the complete analysis for ZLDPF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
